key: cord-1006294-y3yz2x2h
authors: Laveneziana, Pierantonio; Sesé, Lucile; Gille, Thomas
title: Pathophysiology of pulmonary function anomalies in COVID-19 survivors
date: 2021-09-03
journal: Breathe (Sheff)
DOI: 10.1183/20734735.0065-2021
sha: 65df4b96a82e4c5e63deb0bcc578a6258fab01ab
doc_id: 1006294
cord_uid: y3yz2x2h

Coronavirus disease 2019 (COVID-19) is a disease caused by a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-​2), and the predisposing and protecting factors have not been fully elucidated. COVID-19 primarily impacts the respiratory system, and can result in mild illness or serious disease leading to critical illness requiring admission to the intensive care unit due to respiratory failure. After hospital discharge, the more commonly described pulmonary function anomalies are alterations in diffusing capacity and the loss of lung volume. Reduction of inspiratory muscle contraction may also be underestimated. This article will focus on the pathophysiology of pulmonary function anomalies in COVID-19 survivors. We will discuss current advances and provide future directions and also present our perspective on this field.

Coronavirus disease 2019 (COVID-19) is a disease caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily impacts the respiratory system. COVID-19 can result in mild illness or serious disease leading to critical illness requiring admission to an intensive care unit (ICU) due to respiratory failure.

There is intense discussion around potential factors predisposing to and protecting from COVID-19. Children and young people have less severe acute COVID-19 than adults. Severe disease was found to be rare and death exceptionally rare in a large prospective cohort study of children admitted to hospital with laboratory confirmed COVID-19 in the UK [1] . Nonetheless, a study based on data from the National Health Interview Survey in the USA has pointed out that nearly 32% of young adults (aged 18-25 years) and half that (16%) for nonsmoking young adults were found to be medically vulnerable to severe COVID-19 illness [2] . A word of caution is mandatory here because these findings in young adults need to be compared with other indicators related to severe COVID-19 illness, such as hospitalisation rates and mortality.

Smoking appears to be a key factor that confers medical vulnerability among young adults [2] . The risk of severe COVID-19 outcomes is also consistently lower in women than men worldwide, suggesting protective immunomodulatory and anti-inflammatory actions of high physiological concentrations of the steroids 17β-oestradiol (E2) and progesterone (P4) in women [3] . More research is needed in this area. Another issue is the impact of age ≥65 years and the pre-existing concurrent cardiovascular or cerebrovascular diseases that are deemed to be predictors for high mortality of COVID-19 pneumonia [4] .

Pathophysiology of pulmonary function anomalies in COVID- 19 survivors Pulmonary function anomalies in COVID- 19 survivors A major unresolved conundrum is the large spectrum of clinical presentations of patients with COVID-19, ranging from asymptomatic infections or symptomatic mild infections with fever, headache or mild respiratory symptoms (like cough or sore throat) and malaise in 80-85% of patients to flu-like illness and viral pneumonia. Within the "pneumonia phenotype" we also have a large clinical and pathophysiological spectrum that extends from only minor opacification with near normal chest radiographs and mild hypoxaemia (in ∼80% of hospitalised patients). Some of these patients develop an acute respiratory failure with severe hypoxaemia and quick progression to a phenotype presenting with greater hypoxaemia and higher respiratory rates (∼15% of hospitalised patients) to severe disease manifestations. Seriously ill patients develop severe hypoxaemia requiring high-flow oxygen therapy then mechanical ventilation. Their computed tomography (CT) scans document oedema in the lower lobes and multiple ground-glass opacities, angio-CTs may detect micro-embolic lesions and lung ultrasonography that are consistent with interstitial injury with B lines (white lung). This latter phenotype is compatible with either a diffuse alveolar damage or an organising pneumonia with hypoxic vasoconstriction associated with severe hypoxaemia (∼2/3 of patients requiring mechanical ventilation). The last phenotype, less common than the previous one, represents an advanced stage with associated acute lung injury requiring mechanical ventilation [5] . A subset of severe COVID-19 patients also present with coagulation defects with elevated levels of D-dimers and fibrinogen suggesting thrombotic microangiopathy and vasculopathy in the gas-exchange networks and systemically [6] [7] [8] . This latter phenotype suggests a combination of respiratory and vascular dysfunction in the lungs of severely ill COVID-19 patients, which was confirmed in several recent pathological studies [9, 10] . The particular feature of SARS-CoV-2 to induce both respiratory and vascular dysfunction has been established in the past year [11, 12] .

Increasing evidence suggests that these diverse clinical phenotypes might be explained by an immunological failure to control and restrict SARS-CoV-2 infection of the lung. Failure and skewing of the adaptive immune system, promiscuous infection of epithelial (pneumocytes) and endothelial as well as immune cells, coagulation defects and uncontrolled neutrophilic activation potentially govern the impact of COVID-19 on respiratory function and clinical phenotypes (figure 1) [9, [12] [13] [14] [15] . An increased understanding of the respiratory dysfunction underlying the different clinical phenotypes of COVID-19 survivors impacts the management of clinical and pathophysiological consequences of this disease. The pathophysiology of pulmonary function anomalies in COVID-19 survivors will be at the centre of this article. We will discuss current advances and provide future directions and also present our perspective on this field.

Altered lung diffusion capacity is the most common anomaly followed by restrictive ventilatory defect. This section attempts to describe the physiology and pathophysiology that underlies the three most common abnormal pulmonary function variables observed in COVID-19 survivors: transfer factor of the lung for carbon monoxide (T LCO ), T LCO /alveolar volume (V A ) and total lung capacity (TLC). A particular focus will be paid to highlighting the difference between T LCO and K CO and on what is important about having a greater decline in T LCO than in K CO , and how this feeds back to lung pathology.

The lung transfer (or diffusing) capacity for carbon monoxide (T LCO or D LCO ; T LCO being more commonly used in Europe whereas D LCO is more commonly used in North America) reflects the capacity of carbon monoxide transfer from the environment to the pulmonary capillary blood and represents the most clinically practical standard methodology to assess gas exchange in the lung. In this article we will use the term T LCO . K CO , the transfer or diffusion coefficient, is the rate constant for carbon monoxide uptake from alveolar gas and is impacted mostly by the thickness and area of the alveolar capillary membrane, the volume of blood circulating in pulmonary capillaries coupling ventilated alveoli and the concentration and properties of haemoglobin in the alveolar capillaries blood (figure 2). K CO and V A are the two main factors that determine T LCO (figure 2). From a mathematical standpoint, K CO can be calculated as T LCO /V A under BTPS conditions (Body Temperature, ambient Pressure, Saturated with water vapour). It should be noted that K CO is not a simple ratio, as the relationship between lung volume and carbon monoxide uptake is certainly less than 1:1 [16] . The use of K CO has recently been recommended instead of T LCO /V A , as T LCO /V A may be interpreted that T LCO can be normalised for V A [17] .

A low T LCO is not exclusively determined by reduced V A [18] ; residual interstitial anomalies Pulmonary function anomalies in COVID-19 survivors [19] [20] [21] and pulmonary vascular anomalies (i.e. abnormal capillary-alveolar units) [22] may play a fundamental role and this could also be the case in COVID-19 survivors ( figure 3 ). This holds true as the interpretation of low T LCO must consider the complex relationship between V A , T LCO and K CO , and may inopportunely exclude the presence of abnormal gas exchange in the lung (figure 3). To prove this point, we can use data from "severe pneumonia" COVID-19 related patients discussed in this review article to model according to Hughes and Pride [16] what T LCO and K CO responses would be expected if V A was diminished as a consequence of either suboptimal alveolar expansion or due to loss of alveolar units while having a normal expansion in communicating alveoli. We would then observe two trajectories: 1) in the first the decline in T LCO would be largely greater than expected if a decrease in V A was the unique anomaly, regardless of the mechanism behind the diminished V A ; and 2) the second one is that a decrease in V A due to either of the abovementioned mechanisms would be associated with an augmentation in K CO , which would be contrary to the diminished K CO observed in many of the discharged patients with severe COVID-19; therefore, the decrease in K CO may suggest that loss of alveolar units is not sufficient to determine the observed alteration in T LCO . While the anomalies in T LCO observed in patients affected by "severe pneumonia" COVID-19 may be partially explained by diminished V A , the decrease in K CO measured together with the diminished V A also implies that abnormal gas exchange in the lung occurs ( figure 3) . Now, the question arises as whether this is due to anomaly of the alveolar-capillary barrier or to abnormal pulmonary blood volume. Unfortunately, this cannot be easily determined based on data presented in the studies discussed in this review article. Lung fibrosis associated with acute respiratory distress syndrome (ARDS) in COVID-19 patients would likely alter alveolar-capillary units, giving rise to loss of alveolar units and altered gas exchange in the lung. The consequence would be a decrease in both V A and K CO (for that diminished V A ). There is mounting evidence for impaired pulmonary haemodynamics in COVID-19 patients [10] , including vascular pruning, decreased pulmonary blood volume and abnormal pulmonary blood volume distribution as measured via high-resolution CT [23] . Figure 3 shows that a decrease in K CO may develop in the context of alveolar-capillary damage, microvascular pathology, or anaemia. Factors responsible for a reduced V A are numerous and may include decreased alveolar expansion, alveolar damage or loss, or inspired gas maldistribution in the context of an obstructive ventilatory defect. Therefore, when K CO turns normal, in the presence of a low T LCO , it is associated with reduced V A , thus indicating a restrictive ventilatory defect (see below and figure 3 ). This is because only the functional alveolar units have been sampled thereby providing an erroneous picture toward more preserved areas of the lungs ( figure 3 ). It should be noted that if V A is preserved, there is no restrictive ventilatory defect because V A is always a fraction of TLC, i.e. if V A is preserved so is TLC ( figure 3 ). To conclude and for the sake of clarity: the same T LCO may occur with various combinations of V A and K CO , each suggesting different abnormal respiratory conditions. It is difficult to interpret which one plays the predominant role because both diminished V A and K CO concur to the pathogenesis of altered lung diffusion capacity. T LCO gives a global evaluation of gas exchange in the lung, while the alveolar-capillary membrane diffusing capacity only depends on molecular diffusion of the membranes. We would thus need more refined techniques capable of measuring more specifically the alveolar-capillary membrane. These could include measurement of T LCO with inhaled gas mixtures containing two or three different oxygen fractions, or combined T LCO and transfer (or diffusing) capacity measurements of the lung for nitric oxide (T LNO or D LNO ). Such sophisticated analysis could shed light on the precise mechanisms of reduced T LCO in COVID-19 survivors and may allow distinguishing between interstitial and pulmonary capillary anomalies. On this topic, an Italian study by Barisione and Brusasco [24] in 94 patients recovering from mild-to-severe COVID-19 found a greater alteration of T LNO than T LCO , suggesting loss of alveolar units with alveolar membrane damage rather than loss of lung capillary bed (see "Future directions, perspectives and conclusions" section).

The second most common abnormality in COVID-19 survivors is a restrictive ventilatory defect. A restrictive ventilatory defect is defined by a pathologically decreased TLC. If caused by parenchymal lung disease, restrictive ventilatory defect is accompanied by reduced gas transfer, which may be marked clinically by desaturation during exercise or even at rest (see the above paragraph).

TLC is the greatest volume of gas in the lungs achieved after maximal voluntary inspiration. It depends on the static balance between the outward forces generated by inspiratory muscles during a maximal inspiratory effort and the inward elastic forces of the chest wall and lung. It is the lung that normally contributes the most to the elastic recoil forces of the respiratory system at TLC. At TLC, these two sets of forces are equal and opposite in sign. The decrease in TLC usually reflects the reduced lung volumes either because of an alteration in lung parenchyma or because of a disease of the pleura, chest wall, or neuromuscular apparatus that may respectively affect the compliance of the lung or the compliance of the chest wall or the pressuregenerating capacity of the inspiratory muscles. Interstitial lung anomalies, such as those observed in some forms of COVID-19 [25] , may result in a restrictive ventilatory defect (figures 1 and 3).

Respiratory function testing has been performed in COVID-19 survivors at the time of hospital discharge and weeks after hospital discharge. This seems an important issue when dealing with COVID-19 survivors as these respiratory function testing anomalies may have a huge impact on the management, independence and quality of life of these patients as well as on healthcare systems.

In the study by Fumagalli et al. [26] , 13 patients with COVID-19 pneumonia were enrolled and the authors found that at the time of clinical recovery, 10 out of 13 patients presented with a restrictive pattern measured by spirometry: forced expiratory volume in the first second (FEV 1 ) and forced vital capacity (FVC) were lower than lower limit of normality values, while FEV 1 /FVC was higher compared with the upper limit of normality values. These results obtained in a very small sample size should be taken with caution as measurement of TLC, preferably with plethysmography, was not included and the diagnosis of restrictive pattern was made exclusively on the reduced FVC, which is questionable and not acceptable [27] . In addition, T LCO measurement was not employed; this would have permitted a better understanding of the origin and the quality of pulmonary gas exchange damage.

In the study by Mo et al. [20] , 110 patients with COVID-19 infection were enrolled, which included 24 cases of mild illness, 67 cases of pneumonia and 19 cases of severe pneumonia. Spirometry, plethysmography and T LCO tests were performed on the day of or 1 day before hospital discharge. The authors found that 47% of their patients had anomalies in T LCO , 25% in TLC, 14% in FEV 1 , 9% in FVC, 4.5% in the FEV 1 / FVC ratio and 7% in small airway function. The most interesting observation was the significant difference in impaired T LCO among the different groups of severity, which accounted for 30% in mild illness, 42% in pneumonia and 84% in severe pneumonia, respectively (p<0.05). This trend of the gradual decrease in level of T LCO among patients was identical with the varying degree of severity. Of note, in 50% of the T LCOimpaired patients, K CO was still within the normal range, which might indicate that the T LCO decrease was more than the K CO in recovered subjects. In addition, the value of TLC as % of predicted in severe pneumonia cases was much less than that of pneumonia or mild illness, suggesting higher impairment of lung volume in severe cases. No significant difference among the discharged survivors with different severity with regards to other ventilatory defects (e.g. reduced FEV 1 /FVC) was observed.

These two studies, strongly suggest that respiratory function needs to be carefully investigated in COVID-19 patients, as was already done for other atypical pneumonias such as severe influenza A (H1N1) pneumonia [28] . This is because the lung is the most affected organ in COVID-19 and previous other atypical pneumonias, with anomalies that include diffuse alveolar epithelium destruction, capillary damage/bleeding, hyaline membrane formation, alveolar septal fibrous proliferation, and pulmonary consolidation.

In the same study by Fumagalli et al. [26] , FVC was still lower than the lower limit of normality after 6 weeks from hospital discharge. Again, these results obtained in a very small sample size should be taken with caution as measurement of TLC was not included and the diagnosis of restrictive pattern was made exclusively on the reduced FVC, which is questionable and not acceptable [27] . Another study by Huang et al. [29] performed respiratory function testing in 57 COVID-19 patients after 30 days following hospital discharge and found anomalies in 75% of them; 10%, 9%, 44%, 12% and 53% of enrolled patients had FVC, FEV 1 , FEV 1 /FVC ratio, TLC, and T LCO values <80% of predicted values, respectively, whereas 49% and 23% of patients presented with maximum static inspiratory and expiratory pressure (P Imax and P Emax , respectively) values <80% of the corresponding predicted values. Compared with non-severe cases (n=40), severe patients (n=17) showed higher incidence of T LCO impairment (76% versus 43%, p=0.019), and significantly lower percentage of predicted TLC. Of note, only 11% of patients showed obstructive and 12% restrictive ventilatory defects [29] . What is also striking, yet surprising, is that a small percentage of patients with no residual imaging abnormalities presented with a slight decrease in T LCO . Similar to this study, Frija-Masson et al. [30] observed abnormal lung function in more than 50% of COVID-19 patients after 30 days from hospital discharge. One third of the abovementioned patients had decreased T LCO values indicating that these patients have lung vascular damage, which coincides with the data from Huang et al. [29] .

By constrast, Rogliani et al. [31] have recently pointed out that hospitalised patients with mildto-moderate forms of COVID-19 are not at risk of developing pulmonary fibrosis. In their study, patients were enrolled within 2 months from hospital discharge and the authors found that FEV 1 and FVC, both expressed as % predicted, were in the normal range. Again, these results should be taken with caution as neither measurement of TLC nor of T LCO was included in the study.

Several studies have explored pulmonary function in COVID-19 survivors at 3 months [21, [32] [33] [34] [35] and 4 months [36] [37] [38] after hospital discharge. Most of these studies showed alteration in T LCO (in more than 50% of patients), in TLC (in more than 10% of patients), and in pressure-generating capacity of respiratory muscles (in less than 40-50% of patients), but to a much lesser extent alterations in the airway functions (in less than 10% of patients). However, the proportion of altered lung function may be lower in studies that included patients with less severe initial disease [39, 40] . Taken together, these studies strongly converged to the conclusion that the worse the lung involvement during SARS-CoV-2 infection (in those patients who developed ARDS or those who required invasive mechanical ventilation) the worse the impairment in pulmonary function after 3-6 months, especially in terms of T LCO , and the lower the likelihood to normalise pulmonary function over time. Accordingly, Pulmonary function anomalies in COVID-19 survivors respiratory rehabilitation and gradual physical activity immediately after hospital discharge should be encouraged as it can minimise impairment or improve respiratory function such as TLC and T LCO , quality of life and anxiety in these fragile patients [41] .

In conclusion, several mechanisms, sequential or not, may occur and explain the damages induced by SARS-CoV-2 infections of the lungs. They include the microvascular damage with interstitial thickening with clear lungs on radiology examinations along with a severe hypoxaemia [42, 43] , the development of alveolar injury inducing a gradual loss of the alveolar spaces [43] , and last but not least the diminished V A that may be explained by changes in mechanical properties of the lungs and the chest wall and by dysfunction of the respiratory muscles after critical illness. These anomalies can be temporary or responsible for a potential longlasting pulmonary parenchymal dysfunction post-COVID-19 [44] .

Given the interplays discussed above, two hypotheses on reduced T LCO can be proposed in COVID-19 survivors: 1) a reduced T LCO with normal K CO may be in favour of definitive alveolar loss/destruction, with no optimistic perspectives of recovering; 2) a reduced T LCO with diminished K CO may be in favour of alveolar lesions (pulmonary capillary and/or membrane anomalies) that are still evolving, with the optimistic perspective of some and at least partial recovery. We should therefore follow-up COVID-19 survivors to see whether they are able to recover from their T LCO anomalies. Few studies have explored "predictors" for lung function decline, especially for T LCO . Pulmonary interstitial damage (inferred by the chest CT total severity score), the development of acute respiratory distress syndrome, and vascular damage (inferred by high D-dimer levels at the time of hospital admission) have been pointed out as potential predictors for lung function decline, especially for T LCO but also for TLC [21, 22] .

The observations of anomalies in respiratory function, especially in T LCO , in more than 50% of the COVID-19 survivors raises the question of a potential progression towards lung fibrosis in some patients. Interestingly, the greater decline in T LCO compared with K CO suggests that impaired diffusion across the membrane may be more causative for pulmonary dysfunction than reduced lung volume. Previous studies have demonstrated that patients that recovered from coronavirus pneumonia still have damaged lungs. Impaired lung function was common and lasted for months or even years. In follow-up studies on rehabilitating SARS patients lasting from 6 months to 3 years, impaired T LCO was the most common anomaly, ranging from 15% to 44%, followed by reduced TLC, ranging from 5% to 11% [45] [46] [47] . Park et al. [48] showed that 37% of MERS survivors still presented with an impairment of T LCO , but normal TLC at 12 months. In addition, pulmonary function improved significantly in the first 3 months but with no further significant improvement from 3 to 6 months after discharge among survivors of severe influenza A (H1N1) pneumonia [28] . Some other studies showed a complete normalisation of pulmonary function 6 months after H1N1-related ARDS [49] . However, about 80% of survivors of ARDS not provoked by influenza A H1N1 had reduced diffusing capacity, 20% had airway obstruction, and 20% had a restrictive pattern 12 months after recovery [50] . These data are discordant with preliminary follow-up results on COVID-19 survivors highlighting the greater and persistent decline of pulmonary function (T LCO and TLC) in COVID-19 survivors compared with SARS, MERS, and influenza A (H1N1) survivors.

Studies on lung function in COVID-19 survivors at 6 and 12 months from hospital discharge are thus urgently needed in order to monitor the longterm effect of COVID-19 infection on the respiratory system in patients with severe-to-extremelysevere pneumonia. A prediction would be that, at least at 6 months from hospital discharge, these patients may still present with an abnormal T LCO and, to lesser extent, a restrictive ventilatory defect. Indeed, a Chinese study by Huang et al. [51] , conducted at 6 months after hospital discharge, found a T LCO <80% of predicted value in 33% of patients, and a TLC <80% predicted in 16% of patients. Moreover, studies with serial pulmonary function testing would be essential to better assess functional trajectories.

Physiological understanding of early as well as chronic lung responses might be helpful for future stratification of surviving COVID-19 patients with chronic respiratory impairment. In our opinion, potential future directions and perspectives are as follows.

• Pathological and lung function evidence for a vascular component among severe COVID -19 patients, which has long-lasting consequences, should be explored.

• Pathophysiological evidence on deranged adaptive immune function that may drive fibrotic lung diseases and evidence for impaired diffusion capacity in survivors of severe COVID-19 needs to be evaluated.

• More attention should be paid to COVID-19 survivors presenting with impaired (minor or not) diffusion capacity and perhaps with persistent dyspnoea but with no other associated anomalies in chest or CT scan imaging. Techniques capable of measuring more specifically the alveolar-capillary membrane, such as measurement of T LCO including inhaled gas mixtures containing two or three different oxygen fractions or combined T LCO and T LNO measurements, are welcome to shed light on the precise mechanisms of reduced T LCO in COVID-19 survivors particularly in distinguishing between interstitial and pulmonary capillary anomalies.

• More particularly, two hypotheses on reduced T LCO could be tested in COVID-19 survivors: 1) a reduced T LCO with normal K CO may be in favour of definitive alveolar loss/destruction, with no optimistic perspectives of recovering; 2) a reduced T LCO with diminished K CO may be in favour of alveolar lesions (pulmonary capillary and/or membrane anomalies) that are still evolving, with potential and optimistic perspective of some recovery, at least in part. We should therefore follow-up COVID-19 survivors to see whether they are able to recover from their T LCO anomalies.

• A long-lasting follow-up in terms of respiratory function testing is proposed for COVID-19 survivors as results from literature are conflicting as to whether these patients may fully recover or even develop pulmonary sequelae.

This perspective on physiological abnormalities might foster a better understanding of the disease course and may also shape future stratification of patients and treatment options.

Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study

Medical vulnerability of young adults to severe COVID-19 illness-data from the national health interview survey

Estradiol, progesterone, immunomodulation, and COVID-19 outcomes

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

The coagulopathy, endotheliopathy, and vasculitis of COVID-19

SARS-CoV-2 and coagulation disorders in different organs

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19

Novel insights on the pulmonary vascular consequences of COVID-19

Endothelial cell infection and endotheliitis in COVID-19

COVID-19 and cardiovascular consequences: is the endothelial dysfunction the hardest challenge?

The trinity of COVID-19: immunity, inflammation and intervention

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms

In fatal COVID-19, the immune response can control the virus but kill the patient

Examination of the carbon monoxide diffusing capacity (D LCO ) in relation to its K CO and V A components

ERS/ ATS standards for single-breath carbon monoxide uptake in the lung

Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge

Impaired pulmonary function in discharged patients with COVID-19: more work ahead

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up

Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease

Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT

Lung diffusing capacity for nitric oxide and carbon monoxide following mild-to-severe COVID-19

A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression

Pulmonary function in patients surviving to COVID-19 pneumonia

Interpretative strategies for lung function tests

Recovery of pulmonary functions, exercise capacity, and quality of life after pulmonary rehabilitation in survivors of ARDS due to severe influenza A (H1N1) pneumonitis

Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection

Are there pulmonary sequelae in patients recovering from COVID-19?

Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea

A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations

Alteration of diffusion capacity after SARS-CoV-2 infection: a pathophysiological approach

Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae

Mediumterm impact of COVID-19 on pulmonary function, functional capacity and quality of life

Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

lung function and CT findings 3 months after hospital admission for COVID-19

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Respiratory rehabilitation in elderly patients with COVID-19: a randomized controlled study

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

Pulmonary fibrosis secondary to COVID-19: a call to arms?

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Correlation between pneumonia severity and pulmonary complications in Middle East respiratory syndrome

Follow-up after acute respiratory distress syndrome caused by influenza a (H1N1) virus infection

Pulmonary function and health-related quality of life in survivors of acute respiratory distress syndrome

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

P. Laveneziana reports personal fees from Chiesi France, Boehringer Ingelheim France, and Novartis France, outside the submitted work. L. Sesé reports personal fees from Boehringer Ingelheim, Roche and AstraZeneca, and other (congress registration) from Oxyvie (oxygen provider), AstraZeneca and Novartis, outside the submitted work. T. Gille reports personal fees from Boehringer Ingelheim and Roche, other (congress registration) from Oxyvie (oxygen provider), LVL Medical (oxygen provider) and Vitalaire (oxygen provider), outside the submitted work.